312 related articles for article (PubMed ID: 31924403)
1. Atypical Hemolytic Uremic Syndrome After Kidney Transplantation: Lessons Learned From the Good, the Bad, and the Ugly. A Case Series With Literature Review.
Fayek SA; Allam SR; Martinez E; Pan G; Dao A; Rofaiel G
Transplant Proc; 2020; 52(1):146-152. PubMed ID: 31924403
[TBL] [Abstract][Full Text] [Related]
2. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM
Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
[TBL] [Abstract][Full Text] [Related]
4. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience.
Kant S; Bhalla A; Alasfar S; Alachkar N
BMC Nephrol; 2020 May; 21(1):189. PubMed ID: 32434487
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Eculizumab in Kidney Transplant Patients With Primary Atypical Hemolytic-Uremic Syndrome.
González CC; López-Jiménez V; Vázquez-Sánchez T; Vázquez-Sánchez E; Cabello M; Hernández-Marrero D
Transplant Proc; 2022; 54(1):25-26. PubMed ID: 34906374
[TBL] [Abstract][Full Text] [Related]
6. Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort.
Nga HS; Palma LMP; Ernandes Neto M; Fernandes-Charpiot IMM; Garcia VD; Kist R; Miranda SMC; Macedo de Souza PA; Pereira GM; de Andrade LGM
PLoS One; 2021; 16(11):e0258319. PubMed ID: 34748552
[TBL] [Abstract][Full Text] [Related]
7. Renal Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Single Center Experience.
Alpay N; Ozçelik U
Transplant Proc; 2019 Sep; 51(7):2295-2297. PubMed ID: 31400975
[TBL] [Abstract][Full Text] [Related]
8. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
Mallett A; Hughes P; Szer J; Tuckfield A; Van Eps C; Cambell SB; Hawley C; Burke J; Kausman J; Hewitt I; Parnham A; Ford S; Isbel N
Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
[TBL] [Abstract][Full Text] [Related]
10. Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.
Zuber J; Frimat M; Caillard S; Kamar N; Gatault P; Petitprez F; Couzi L; Jourde-Chiche N; Chatelet V; Gaisne R; Bertrand D; Bamoulid J; Louis M; Sberro Soussan R; Navarro D; Westeel PF; Frimat L; Colosio C; Thierry A; Rivalan J; Albano L; Arzouk N; Cornec-Le Gall E; Claisse G; Elias M; El Karoui K; Chauvet S; Coindre JP; Rerolle JP; Tricot L; Sayegh J; Garrouste C; Charasse C; Delmas Y; Massy Z; Hourmant M; Servais A; Loirat C; Fakhouri F; Pouteil-Noble C; Peraldi MN; Legendre C; Rondeau E; Le Quintrec M; Frémeaux-Bacchi V
J Am Soc Nephrol; 2019 Dec; 30(12):2449-2463. PubMed ID: 31575699
[TBL] [Abstract][Full Text] [Related]
11. Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report.
Dedhia P; Govil A; Mogilishetty G; Alloway RR; Woodle ES; Abu Jawdeh BG
Transplant Proc; 2017; 49(1):188-192. PubMed ID: 28104134
[TBL] [Abstract][Full Text] [Related]
12. Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.
Vondrák K; Seeman T
Transplant Proc; 2018 Apr; 50(3):967-970. PubMed ID: 29661469
[TBL] [Abstract][Full Text] [Related]
13. Transplantation in pediatric aHUS within the era of eculizumab therapy.
Özçakar ZB; Ozaltin F; Gülhan B; Çomak E; Parmaksız G; Baskın E; Topaloğlu R; Kasap Demir B; Canpolat N; Yuruk Yildirim Z; Demircioğlu Kılıç B; Yüksel S; Söylemezoğlu O
Pediatr Transplant; 2021 May; 25(3):e13914. PubMed ID: 33217100
[TBL] [Abstract][Full Text] [Related]
14. Adult Post-Kidney Transplant Familial Atypical Hemolytic Uremic Syndrome Successfully Treated With Eculizumab: A Case Report and Literature Review.
Salameh H; Abu Omar M; Alhariri A; Kisra S; Qasem A; Abdulhak AB
Am J Ther; 2016; 23(4):e1110-5. PubMed ID: 25486517
[TBL] [Abstract][Full Text] [Related]
15. Liver transplantation for aHUS: still needed in the eculizumab era?
Coppo R; Bonaudo R; Peruzzi RL; Amore A; Brunati A; Romagnoli R; Salizzoni M; Galbusera M; Gotti E; Daina E; Noris M; Remuzzi G
Pediatr Nephrol; 2016 May; 31(5):759-68. PubMed ID: 26604087
[TBL] [Abstract][Full Text] [Related]
16. Atypical hemolytic uremic syndrome recurrence after kidney transplantation.
Matar D; Naqvi F; Racusen LC; Carter-Monroe N; Montgomery RA; Alachkar N
Transplantation; 2014 Dec; 98(11):1205-12. PubMed ID: 24933457
[TBL] [Abstract][Full Text] [Related]
17. Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.
Alobaidi S; AlDabbagh A; Alamoudi A; Almowarey M; Akl A
CEN Case Rep; 2019 May; 8(2):139-143. PubMed ID: 30715674
[TBL] [Abstract][Full Text] [Related]
18. [Use of Eculizumab in atypical hemolytic uremic syndrome after renal transplantation].
Teixeira CI; Mota RG; Afonso BG; Carneiro TV; Meira GS; Mendonça DU
J Bras Nefrol; 2015; 37(1):127-30. PubMed ID: 25923760
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome.
van den Brand JA; Verhave JC; Adang EM; Wetzels JF
Nephrol Dial Transplant; 2017 Jan; 32(suppl_1):i115-i122. PubMed ID: 28391343
[TBL] [Abstract][Full Text] [Related]
20. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.
Fakhouri F; Fila M; Hummel A; Ribes D; Sellier-Leclerc AL; Ville S; Pouteil-Noble C; Coindre JP; Le Quintrec M; Rondeau E; Boyer O; Provôt F; Djeddi D; Hanf W; Delmas Y; Louillet F; Lahoche A; Favre G; Châtelet V; Launay EA; Presne C; Zaloszyc A; Caillard S; Bally S; Raimbourg Q; Tricot L; Mousson C; Le Thuaut A; Loirat C; Frémeaux-Bacchi V
Blood; 2021 May; 137(18):2438-2449. PubMed ID: 33270832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
